Study description: STRIVE (Study of TYSABRI in Early Relapsing-RemItting Multiple Sclerosis in Anti-JCV Antibody NegatiVE Patients) was a 4-year, multicenter, observational, open-label, single-arm study conducted in the United States. Patients were anti-JCV antibody negative ≤6 months prior to screening or at baseline and were prescribed natalizumab 300 mg IV ≤3 years after RRMS diagnosis; 47% of patients (n=105) completed all 4 years on TYSABRI, while 41% (n=91) discontinued TYSABRI and 30% (n=67) withdrew prior to Year 4.
Study limitations:
bp values are based on unadjusted logistic regression models. Patients with NEDA status available during both the first and fourth years are included.
The STRIVE study was funded by Biogen.